Tern extends Device Authority convertible loan note maturity date

Money and Investment

Tern Plc (LON:TERN), the investment company specialising in the Internet of Things, has announced that the maturity date for all convertible loan notes provided to Device Authority Limited by Tern, Alsop Louie Partners and the George Samenuk Family Trust et al., has been extended to 31 March 2022.  

All existing repayment and conversion rights, automatic and at the holder’s option, have also been extended to 31 March 2022.  All other terms of these loan notes remain unchanged and as previously announced.

The outstanding convertible loan balance payable by Device Authority to Tern currently stands at US$4.3 million, excluding US$0.6 million of interest accrued to date.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AI search visibility becomes a strategic digital asset

Generative Engine Optimisation is becoming a new layer of digital visibility as AI platforms reshape how brands are discovered, trusted and evaluated.

Device Authority targets a core security gap in healthcare

Device Authority says healthcare must secure legacy medical devices by putting trusted device identity at the centre of cybersecurity strategy.

Evidence-based personas put behaviour at the centre of customer intelligence

Evidence-based personas shift customer intelligence from what people might say to what they are likely to do.

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

Search